Xtant Medical Holdings, Inc. (XTN) is a leading global medical technology company that specializes in the design, development, manufacturing, and distribution of innovative solutions for the treatment of degenerative, trauma, and disease-impacted orthopedic and neurological conditions. Xtant's comprehensive portfolio comprises regenerative medical products, fixation devices, and orthobiologics designed to improve patient outcomes. Listed on NYSE, the company's stock trades under the symbol 'XTNT'.
The company was founded in 2006 and originally ran as Bacterin International Holdings before rebranding to Xtant Medical in 2015 to reflect its focus on combining biologics with medical devices in order to provide truly comprehensive therapeutic solutions. This specialization has set Xtant apart, earning the company recognition for its deep-seated commitment to innovation, its extensive scientific research, and high-quality product portfolio.
Xtant operates under a customer-driven approach, committed to excellence across all its operations. The company focuses on obtaining an in-depth understanding of the complex needs of its customers and the industry as a whole. The team at Xtant, comprising medical researchers, engineers, and business professionals, work together to create processes and technologies to deliver a variety of cutting-edge orthopedic products, offering optimal patient care solutions to healthcare providers worldwide.
One of the company's differentiators lies in it's advanced orthobiologics product line, which includes demineralized bone matrix, traditional allografts, and synthetic bone graft substitutes. These products are designed to enhance the body's natural healing processes, improve surgical outcomes, and reduce recovery times.
Moreover, Xtant is heavily invested in research and development, aiming to continuously evolve its product offerings to stay ahead of emerging industry trends and the ever-changing needs of its customers. This dedication to innovation has allowed Xtant to maintain a leading role in the medical technology industry and underpin its commitment to improving patient health and quality of life.
In addition, Xtant Medical Holdings, Inc. operates with a deep sense of corporate responsibility. It is dedicated to upholding the highest standards of corporate governance, ethical business conduct and regulatory compliance. The team adheres to a stringent quality management system that complies with regulatory requirements in order to ensure the safety, effectiveness, and quality of its products.
As of today, Xtant Medical Holdings, Inc. continues its mission of becoming a global leader in regenerative medicine, continuously innovating, and meeting the evolving needs of the healthcare community in the pursuit of enhancing the quality of life of patients worldwide.